NCMAG117 Dasatinib advice document: July 2024
Posted on:
Document Type
NCMAG advice
Process guidance
Summary
For the treatment of adult patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia with resistance or intolerance to prior therapy. (On-label use and off-patent medicine.)
Decision: supported